EnteroBiotix

Name

EnteroBiotix

Legal name

EnteroBiotix Limited

Website

https://enterobiotix.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Microbiome Therapeutics

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery) (HLAAAFAJ)

akta.pro secondary industries

Microbiome Clinical Development & Translational Services (trial design, endpoints, sampling) (HLAAAFAK), Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI)

Keywords

• Microbiome therapeutics
• Full-spectrum microbiome drugs
• Gut health therapeutics
• Biologics GMP manufacturing
• Clinical-stage biopharmaceuticals

Headquarters

HQ city

Edinburgh

HQ country

United Kingdom

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Future Out-licensing / Partnerships: Clinical-stage company; not yet generating product revenue. Actively seeking licensing partners for late-stage clinical development and commercialisation of lead asset EBX-102-02. Future revenue expected via licensing deals, milestone payments, and royalties upon commercialisation.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels7 records

Core offering

EnteroBiotix is a clinical-stage biopharmaceutical company developing full-spectrum microbiome therapeutics, with lead candidate EBX-102-02® — an orally administered, high-diversity microbial product formulated as a stable, off-white, odourless powder via the proprietary AMPLA™ drying technology. The candidate is in clinical development for irritable bowel syndrome (IBS-C and IBS-D), liver cirrhosis and hepatic encephalopathy, and as adjuvant therapy in allogeneic haematopoietic stem cell transplantation. The company controls its supply chain end-to-end through the Number2® donor programme, MHRA-licensed GMP manufacturing facilities in Glasgow and Aberdeen, and the PRISM analytical toolkit.

Product overview

EnteroBiotix operates a platform-plus-modules architecture centred on its proprietary full-spectrum microbiome therapeutics platform. The core lead asset is the orally delivered, full-spectrum microbiome drug EBX-102-02® (with predecessor EBX-102), currently in clinical development for irritable bowel syndrome (IBS, both IBS-C and IBS-D subtypes), liver cirrhosis and hepatic encephalopathy, and as adjuvant treatment in allogeneic haematopoietic stem cell transplantation (allo-HSCT). Manufacturing is enabled by the proprietary AMPLA™ drying platform, which produces stable, off-white, odourless orally dosed powder without lyophilization. Supply of raw microbiota is controlled end-to-end through the Number2® donor programme (Number2.org), and product quality/characterisation is supported by the PRISM analytical and bioinformatics toolkit, all anchored within MHRA-licensed GMP facilities in Glasgow and Aberdeen. The Inside Matters site operates as an associated consumer-facing brand under the same legal entity.

Differentiator

Problem solved

Functional benefit

Brands

• Number 2®: Donor programme and donor-facing platform/Number2.org site operated by EnteroBiotix to source, screen and manage healthy human microbiota donors underpinning its full-spectrum microbiome therapeutics.
• EBX-102-02®
• EBX-102
• AMPLA™
• Mastering the microbiome®

Products and services

• EBX-102-02® Next-generation, orally administered, full-spectrum microbiome therapeutic in clinical development for irritable bowel syndrome (IBS-C and IBS-D), liver cirrhosis and hepatic encephalopathy, and as adjuvant treatment in allogeneic haematopoietic stem cell transplantation. Formulated as a high-diversity, off-white, odourless powder manufactured via the proprietary AMPLA™ drying technology; protected by granted composition-of-matter patents.
• EBX-102 Predecessor full-spectrum microbiome therapeutic from EnteroBiotix, evaluated in the IMPuLCE Phase 1b and Phase 2 clinical trials in liver cirrhosis and hepatic encephalopathy. Manufactured using the proprietary AMPLA™ technology and formulated as a high-diversity oral powder.

Quantifiable outcome

• 59% responder rate at Week 7 on EBX-102-02 vs 44% on placebo using ≥50-point IBS-SSS reduction threshold; 51% vs 33% using ≥75-point threshold.
• +4 more outcomes

Named customers1 record

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered flagship and core.

• Imperial College LondonflagshipStrategic or Co-development Partner · 10 November 2022Strategic partnership announced November 2022 for the MAST (Microbiota Transplant Prior to Allogeneic Stem Cell Transplantation) Phase IIa investigator-initiated trial. Combines Imperial's expertise with EnteroBiotix's AMPLA™ platform and MHRA-licensed facilities. EnteroBiotix supplies EBX-102 from its MHRA-licensed facilities for the clinical trial. Trial runs across six UK blood cancer centres (Imperial, UCLH, The Royal Marsden, King's College London, Leeds Teaching Hospitals, University Hospitals Birmingham). Funded by the Medical Research Council with in-kind support from EnteroBiotix. Topline data expected H1 2027.
• Functional Gut Clinic (FGC)coreImplementation/ SI/ Consulting PartnerUK-based clinical delivery partner for the TrIuMPH Phase 2a trial across two UK sites. FGC is the UK's leading provider of Functional GI Diagnostic Testing with sites in London, Manchester and Cambridge; operates with IQIPS/UKAS and CQC accreditation. Supports patient recruitment and clinical operations.
• University of Glasgow / Glasgow Royal Infirmary (Ewan Forrest)coreStrategic or Co-development PartnerProfessor Ewan Forrest (Consultant Hepatologist at Glasgow Royal Infirmary and Honorary Professor at University of Glasgow) is Chief Investigator of the IMPuLCE Phase 1b/2 trial evaluating EBX-102 in liver cirrhosis and hepatic encephalopathy. Presents at EASL Congress 2025.
• University of Manchester NHS Trust (Paul Goldsmith)coreStrategic or Co-development PartnerMr Paul Goldsmith MD, FRCS, Consultant General Surgeon at the University of Manchester NHS Trust, serves as Chief Investigator of the TrIuMPH Phase 2a study of EBX-102-02 in IBS.

Scale indicators13 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• MaaT Pharma: European clinical-stage microbiome therapeutics company developing full-spectrum, donor-derived, standardised microbiota products for oncology and GI indications. Closely comparable to EnteroBiotix in donor-derived full-spectrum platform, GMP manufacturing, and indication pipeline (including haemato-oncology).
• Seres Therapeutics: Clinical-stage microbiome therapeutics company developing full-spectrum and defined live biotherapeutic products for GI and other indications. Closely comparable to EnteroBiotix in platform approach (full-spectrum microbiome drug), therapeutic area focus, and regulatory stage.
• Finch Therapeutics: Was a clinical-stage microbiome therapeutics company developing full-spectrum microbial treatments; comparable to EnteroBiotix in full-spectrum approach and GI indications, and a useful benchmark for the operational and clinical risks in the space.
• 4D pharma: Clinical-stage live biotherapeutic company developing single-strain and defined microbiome therapeutics for cancer and GI disease. Comparable to EnteroBiotix as a clinical-stage microbiome peer with pipeline overlap in oncology supportive care and GI indications.
• Vedanta Biosciences: Developer of defined bacterial consortium therapies for GI and immune-mediated diseases. Comparable to EnteroBiotix as a microbiome therapeutics peer pursuing oral, GMP-manufactured live biotherapeutics, although Vedanta uses rationally defined consortia versus EnteroBiotix's full-spectrum approach.

Broad incumbents

• Ferring Pharmaceuticals (Rebiotix): Through Rebiotix, Ferring markets the first FDA-approved fecal microbiota product (Rebyota) and is developing microbiome-based therapeutics broadly. A broad incumbent in the same therapeutic category with deeper commercial reach than EnteroBiotix.

Emerging players

• Assembly Biosciences: Clinical-stage biopharmaceutical company developing microbiome-targeted therapeutics for GI and other diseases. Comparable to EnteroBiotix as a smaller microbiome-focused peer pursuing oral microbiome drug development.
• Second Genome: Clinical-stage microbiome drug discovery and development company focused on GI and metabolic diseases. Comparable to EnteroBiotix as an emerging clinical-stage microbiome therapeutics peer.
• BiomX: Clinical-stage company developing phage and microbiome-based therapeutics for GI and skin diseases. Partially comparable to EnteroBiotix as a clinical-stage microbiome therapeutics peer, though focused on phage-based approaches.
• Eligo Bioscience: Developer of microbiome-targeted therapeutics using engineered phage and synthetic biology approaches for GI and other diseases. Comparable to EnteroBiotix as a microbiome therapeutics peer targeting the gut microbiome with a novel platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/enterobiotix
• Xx.com/enterobiotix
• Facebookfacebook.com/EnteroBiotix

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries1 record

Funding overview

Funding rounds7 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EnteroBiotix